Johnson & Johnson

Shares of Johnson & Johnson dipped 2% on Wednesday after a jury awarded $8 billion in punitive damages to a man who accused the drugmaker of failing to warn that young men using its antipsychotic drug Risperdal could grow breasts.

Johnson & Johnson must pay $8 billion in punitive damages to a man who previously won $680,000 over his claims that it failed to warn that young men using its antipsychotic drug Risperdal could grow breasts, a Philadelphia jury said on Tuesday.

Oklahoma's attorney general has moved to appeal a judge's ruling holding that state had only established it was entitled to just $572 million of the $17 billion it requested on its claims that Johnson & Johnson fueled the opioid epidemic through deceptive painkiller marketing...

A federal judge has cleared the way for an ex-Acclarent Inc sales representative to take the Johnson & Johnson unit to trial over her claim it wrongfully fired her because she refused to promote a medical device for unapproved uses.

Johnson & Johnson said on Tuesday it will pay $20.4 million to settle claims by two Ohio counties, allowing the U.S. healthcare giant to avoid an upcoming federal trial seeking to hold the industry responsible for the nation's opioid epidemic.

Johnson & Johnson said on Tuesday it will pay $20.4 million to settle claims by two Ohio counties, allowing the U.S. healthcare giant to avoid an upcoming federal trial seeking to hold the industry responsible for the nation's opioid epidemic.

Johnson & Johnson said on Tuesday it settled with two Ohio counties, ahead of an opioid trial scheduled to begin on Oct. 21.

Endo International Plc, Johnson & Johnson and other drugmakers that face litigation over the opioid crisis are exploring a way to settle the cases by participating in Purdue Pharma LP's bankruptcy, the Wall Street Journal reported, citing internal documents and a person...

Endo International Plc, Johnson & Johnson and other drugmakers that face litigation over the opioid crisis are exploring a way to settle the cases by participating in Purdue Pharma LP's bankruptcy, the Wall Street Journal reported, citing internal documents and a person...

A drug wholesaler must submit its claims that Johnson & Johnson is illegally suppressing competition for its rheumatoid arthritis treatment Remicade to an arbitrator, a federal appeals court held on Friday.

Bayer <BAYGn.DE> said it hired Johnson & Johnson <JNJ.N> executive Marianne De Backer to manage acquisitions and licensing deals at its drugs unit, as the German drugmaker turns to outside sources to boost its development pipeline.

* Dow down 0.35%, S&P 500 down 0.28%, Nasdaq down 0.39% (Updates to mid-afternoon, changes byline)

* Indexes: Dow & S&P 500 flat, Nasdaq off 0.04% (Updates prices, comments)

An Oklahoma judge on Monday ordered Johnson & Johnson <JNJ.N> to pay $572.1 million to the state for its part in fueling an opioid epidemic by deceptively marketing addictive painkillers, a sum that was substantially less than investors had expected, driving up J&J's shares.

A lawsuit by Oklahoma's attorney general accusing Johnson & Johnson of fueling the opioid epidemic is set to establish a major precedent over whether a state's public nuisance laws can be used to hold a drugmaker liable for the U.S. drug crisis.

British drugmaker GlaxoSmithKline is giving up its work on developing three potential vaccines against the deadly Ebola and Marburg viruses, despite an ongoing Ebola outbreak in Democratic Republic of Congo.

Oklahoma's attorney general on Wednesday made his final bid to force Johnson & Johnson to pay $17 billion for its part in fueling the opioid epidemic, saying the drugmaker's "egregious" marketing caused an oversupply of addictive drugs and overdose deaths.

The Federal Trade Commission issued civil subpoenas to Johnson and Johnson in June as part of an investigation into whether contracting practices for its blockbuster rheumatoid arthritis drug, Remicade, violated antitrust laws, the company said in a regulatory filing on...

Johnson & Johnson <JNJ.N> on Tuesday boosted its 2019 sales forecast amid robust demand for its cancer drugs, but warned that competition from generic and copycat drugs could impact its third-quarter results, sending shares down 1.4% in noon trading.